{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:02:23Z","timestamp":1771351343014,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10072-025-08748-w","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:44:32Z","timestamp":1769831072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Catecholaminergic storm and extreme blood pressure lability induced by combined levodopa\/benserazide, selegiline, and piribedil in Parkinson\u2019s disease: a case report"],"prefix":"10.1007","volume":"47","author":[{"given":"Yuhan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingguo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanmei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"8748_CR1","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JST, Zhang J, Yan R, Zheng X, Wu J, Zhao D, Wang A, Zhou M, Feng T (2025) Projections for prevalence of parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of global burden of disease study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"key":"8748_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670\u20131683. https:\/\/doi.org\/10.1001\/jama.2014.3654","journal-title":"JAMA"},{"key":"8748_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","volume":"172","author":"A Elbaz","year":"2016","unstructured":"Elbaz A, Carcaillon L, Kab S, Moisan F (2016) Epidemiology of parkinson\u2019s disease. Rev Neurol (Paris) 172:14\u201326. https:\/\/doi.org\/10.1016\/j.neurol.2015.09.012","journal-title":"Rev Neurol (Paris)"},{"key":"8748_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mds.26079","volume":"30","author":"JA Palma","year":"2015","unstructured":"Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, Kaufmann H (2015) Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 30:639\u2013645. https:\/\/doi.org\/10.1002\/mds.26079","journal-title":"Mov Disord"},{"key":"8748_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fneur.2013.00049","volume":"4","author":"E Stuebner","year":"2013","unstructured":"Stuebner E, Vichayanrat E, Low DA, Mathias CJ, Isenmann S, Haensch CA (2013) Twenty-four hour non-invasive ambulatory blood pressure and heart rate monitoring in parkinson\u2019s disease. Front Neurol 4:49. https:\/\/doi.org\/10.3389\/fneur.2013.00049","journal-title":"Front Neurol"},{"key":"8748_CR6","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1161\/hypertensionaha.115.05913","volume":"66","author":"V Milazzo","year":"2015","unstructured":"Milazzo V, Maule S, Di Stefano C, Tosello F, Totaro S, Veglio F, Milan A (2015) Cardiac organ damage and arterial stiffness in autonomic failure: comparison with essential hypertension. Hypertension 66:1168\u20131175. https:\/\/doi.org\/10.1161\/hypertensionaha.115.05913","journal-title":"Hypertension"},{"key":"8748_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with Levodopa. Arch Neurol 21:343\u2013354. https:\/\/doi.org\/10.1001\/archneur.1969.00480160015001","journal-title":"Arch Neurol"},{"key":"8748_CR8","doi-asserted-by":"publisher","first-page":"e16061","DOI":"10.1111\/ene.16061","volume":"31","author":"I Cani","year":"2024","unstructured":"Cani I, Guaraldi P, Giannini G (2024) Levodopa-induced orthostatic hypotension in parkinsonism: A red flag of autonomic failure. Eur J Neurol 31:e16061. https:\/\/doi.org\/10.1111\/ene.16061","journal-title":"Eur J Neurol"},{"key":"8748_CR9","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10072-022-06499-6","volume":"44","author":"H Murakami","year":"2023","unstructured":"Murakami H, Okumura M, Ozawa M, Mimori M, Maku T, Shiraishi T, Kitagawa T, Takatsu H, Sato T, Komatsu T, Sakai K, Umehara T, Omoto S, Mitsumura H, Iguchi Y (2023) Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in parkinson\u2019s disease are dependent on frontal function. Neurol Sci 44:913\u2013918. https:\/\/doi.org\/10.1007\/s10072-022-06499-6","journal-title":"Neurol Sci"},{"key":"8748_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/1531-8257(199903)14:2<246::aid-mds1008>3.0.co;2-p","volume":"14","author":"A Churchyard","year":"1999","unstructured":"Churchyard A, Mathias CJ, Lees AJ (1999) Selegiline-induced postural hypotension in parkinson\u2019s disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 14:246\u2013251. https:\/\/doi.org\/10.1002\/1531-8257(199903)14:2%3C246::aid-mds1008%3E3.0.co;2-p","journal-title":"Mov Disord"},{"key":"8748_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/ageing\/31.3.181","volume":"31","author":"E Heitterachi","year":"2002","unstructured":"Heitterachi E, Lord SR, Meyerkort P, McCloskey I, Fitzpatrick R (2002) Blood pressure changes on upright tilting predict falls in older people. Age Ageing 31:181\u2013186. https:\/\/doi.org\/10.1093\/ageing\/31.3.181","journal-title":"Age Ageing"},{"key":"8748_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","volume":"128","author":"MJ Millan","year":"2010","unstructured":"Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D\u2082\/D\u2083receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of parkinson\u2019s disease. Pharmacol Ther 128:229\u2013273. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.06.002","journal-title":"Pharmacol Ther"},{"key":"8748_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/j.1552-4604.1992.tb03788.x","volume":"32","author":"A Luchsinger","year":"1992","unstructured":"Luchsinger A, Velasco M, Urbina A, Morillo J, Romero E, Alvarez R, Pieretti OH (1992) Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. J Clin Pharmacol 32:55\u201360. https:\/\/doi.org\/10.1002\/j.1552-4604.1992.tb03788.x","journal-title":"J Clin Pharmacol"},{"key":"8748_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0163-7258(98)00027-8","volume":"80","author":"PA Jose","year":"1998","unstructured":"Jose PA, Eisner GM, Felder RA (1998) Renal dopamine receptors in health and hypertension. Pharmacol Ther 80:149\u2013182. https:\/\/doi.org\/10.1016\/s0163-7258(98)00027-8","journal-title":"Pharmacol Ther"},{"key":"8748_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0163-7258(99)00029-7","volume":"84","author":"G Emilien","year":"1999","unstructured":"Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S (1999) Dopamine receptors\u2013physiological Understanding to therapeutic intervention potential. Pharmacol Ther 84:133\u2013156. https:\/\/doi.org\/10.1016\/s0163-7258(99)00029-7","journal-title":"Pharmacol Ther"},{"key":"8748_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1600-0404.1991.tb05023.x","volume":"136","author":"VV Myllyl\u00e4","year":"1991","unstructured":"Myllyl\u00e4 VV, Sotaniemi KA, Vuorinen JA, Heinonen EH (1991) Selegiline as a primary treatment of parkinson\u2019s disease. Acta Neurol Scand Suppl 136:70\u201372. https:\/\/doi.org\/10.1111\/j.1600-0404.1991.tb05023.x","journal-title":"Acta Neurol Scand Suppl"},{"key":"8748_CR17","doi-asserted-by":"publisher","unstructured":"Harsing LG Jr., Timar J, Miklya I (2023) Striking neurochemical and behavioral differences in the mode of action of selegiline and Rasagiline. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241713334","DOI":"10.3390\/ijms241713334"},{"key":"8748_CR18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-016-0360-5","volume":"30","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Rascol O (2016) Piribedil for the treatment of motor and Non-motor symptoms of Parkinson disease. CNS Drugs 30:703\u2013717. https:\/\/doi.org\/10.1007\/s40263-016-0360-5","journal-title":"CNS Drugs"},{"key":"8748_CR19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0022-3565(25)12143-5","volume":"275","author":"A Gobert","year":"1995","unstructured":"Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and silent D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 275:899\u2013913","journal-title":"J Pharmacol Exp Ther"},{"key":"8748_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1034\/j.1600-0404.2003.00172.x","volume":"109","author":"A Korchounov","year":"2004","unstructured":"Korchounov A, Kessler KR, Schipper HI (2004) Differential effects of various treatment combinations on cardiovascular dysfunction in patients with parkinson\u2019s disease. Acta Neurol Scand 109:45\u201351. https:\/\/doi.org\/10.1034\/j.1600-0404.2003.00172.x","journal-title":"Acta Neurol Scand"},{"key":"8748_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00002826-200009000-00006","volume":"23","author":"JL Montastruc","year":"2000","unstructured":"Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri H, Rascol O, Lapeyre-Mestre M (2000) Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol 23:271\u2013275. https:\/\/doi.org\/10.1097\/00002826-200009000-00006","journal-title":"Clin Neuropharmacol"},{"key":"8748_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1212\/wnl.48.3.662","volume":"48","author":"J Turkka","year":"1997","unstructured":"Turkka J, Suominen K, Tolonen U, Sotaniemi K, Myllyl\u00e4 VV (1997) Selegiline diminishes cardiovascular autonomic responses in parkinson\u2019s disease. Neurology 48:662\u2013667. https:\/\/doi.org\/10.1212\/wnl.48.3.662","journal-title":"Neurology"},{"key":"8748_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s1353-8020(02)00053-6","volume":"9","author":"KF Bhattacharya","year":"2003","unstructured":"Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H (2003) Selegiline in the treatment of parkinson\u2019s disease: its impact on orthostatic hypotension. Parkinsonism Relat Disord 9:221\u2013224. https:\/\/doi.org\/10.1016\/s1353-8020(02)00053-6","journal-title":"Parkinsonism Relat Disord"},{"key":"8748_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/jnnp.63.2.228","volume":"63","author":"A Churchyard","year":"1997","unstructured":"Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ (1997) Autonomic effects of selegiline: possible cardiovascular toxicity in parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 63:228\u2013234. https:\/\/doi.org\/10.1136\/jnnp.63.2.228","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8748_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10072-015-2395-7","volume":"37","author":"L Degli Esposti","year":"2016","unstructured":"Degli Esposti L, Piccinni C, Sangiorgi D, Nobili F, Buda S (2016) Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between Rasagiline and selegiline. Neurol Sci 37:227\u2013234. https:\/\/doi.org\/10.1007\/s10072-015-2395-7","journal-title":"Neurol Sci"},{"key":"8748_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of Rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241\u2013248. https:\/\/doi.org\/10.1001\/archneur.62.2.241","journal-title":"Arch Neurol"},{"key":"8748_CR27","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-015-0293-4","volume":"29","author":"T Tran","year":"2015","unstructured":"Tran T, Brophy JM, Suissa S, Renoux C (2015) Risks of cardiac valve regurgitation and heart failure associated with Ergot- and Non-Ergot-Derived dopamine agonist use in patients with parkinson\u2019s disease: A systematic review of observational studies. CNS Drugs 29:985\u2013998. https:\/\/doi.org\/10.1007\/s40263-015-0293-4","journal-title":"CNS Drugs"},{"key":"8748_CR28","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","volume":"57","author":"K Kujawa","year":"2000","unstructured":"Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG (2000) Acute orthostatic hypotension when starting dopamine agonists in parkinson\u2019s disease. Arch Neurol 57:1461\u20131463. https:\/\/doi.org\/10.1001\/archneur.57.10.1461","journal-title":"Arch Neurol"},{"key":"8748_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/ibpc.s34803","volume":"6","author":"PA Meredith","year":"2013","unstructured":"Meredith PA, Elliott HL (2013) A review of the Gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on Nifedipine GITS). Integr Blood Press Control 6:79\u201387. https:\/\/doi.org\/10.2147\/ibpc.s34803","journal-title":"Integr Blood Press Control"},{"key":"8748_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.62347\/rpmz6407","volume":"14","author":"PK Hazra","year":"2024","unstructured":"Hazra PK, Mehta A, Desai B, Pandey U, Mehta KD, Bajpai S, Prasad D (2024) Long-acting Nifedipine in the management of essential hypertension: a review for cardiologists. Am J Cardiovasc Dis 14:396\u2013413. https:\/\/doi.org\/10.62347\/rpmz6407","journal-title":"Am J Cardiovasc Dis"},{"key":"8748_CR31","doi-asserted-by":"publisher","unstructured":"S\u00e9nard JM, Verwaerde P, Rascol O, Montastruc JL (1995) Effects of acute Levodopa administration on blood pressure and heart variability in never treated parkinsonians. Hypertens Res 18 Suppl 1S175\u2013S177. https:\/\/doi.org\/10.1291\/hypres.18.supplementi_s175","DOI":"10.1291\/hypres.18.supplementi_s175"},{"key":"8748_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1053\/j.ajkd.2007.10.044","volume":"51","author":"M Dickenmann","year":"2008","unstructured":"Dickenmann M, Oettl T, Mihatsch MJ (2008) Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 51:491\u2013503. https:\/\/doi.org\/10.1053\/j.ajkd.2007.10.044","journal-title":"Am J Kidney Dis"},{"key":"8748_CR33","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/jci129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, Consiglio A, Raya A, Polgreen PM, Narayanan NS, Yuan Y, Chen Z, Su W, Han Y, Zhao C, Gao L, Ji X, Welsh MJ, Liu L (2019) Enhancing Glycolysis attenuates parkinson\u2019s disease progression in models and clinical databases. J Clin Invest 129:4539\u20134549. https:\/\/doi.org\/10.1172\/jci129987","journal-title":"J Clin Invest"},{"key":"8748_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nchembio.1657","volume":"11","author":"X Chen","year":"2015","unstructured":"Chen X, Zhao C (2015) Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nat Chem Biol 11:19\u201325. https:\/\/doi.org\/10.1038\/nchembio.1657","journal-title":"Nat Chem Biol"},{"key":"8748_CR35","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/jch.14556","volume":"24","author":"H Li","year":"2022","unstructured":"Li H, Xu TY, Li Y (2022) Role of \u03b11-blockers in the current management of hypertension. J Clin Hypertens (Greenwich) 24:1180\u20131186. https:\/\/doi.org\/10.1111\/jch.14556","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl 1","key":"8748_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000116170","volume":"27","author":"M Da Prada","year":"1987","unstructured":"Da Prada M, Kettler R, Z\u00fcrcher G, Schaffner R, Haefely WE (1987) Inhibition of decarboxylase and levels of Dopa and 3-O-methyldopa: a comparative study of Benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 27(Suppl 1):9\u201320. https:\/\/doi.org\/10.1159\/000116170","journal-title":"Eur Neurol"},{"key":"8748_CR37","doi-asserted-by":"publisher","first-page":"1529932","DOI":"10.3389\/fphar.2025.1529932","volume":"16","author":"H Qiu","year":"2025","unstructured":"Qiu H, Liu C, Wang Z (2025) Levodopa-induced motor complications associated with Benserazide and carbidopa in parkinson\u2019s disease: a disproportionality analysis of the FAERS database. Front Pharmacol 16:1529932. https:\/\/doi.org\/10.3389\/fphar.2025.1529932","journal-title":"Front Pharmacol"},{"key":"8748_CR38","doi-asserted-by":"publisher","first-page":"e17876","DOI":"10.1016\/j.heliyon.2023.e17876","volume":"9","author":"D Su","year":"2023","unstructured":"Su D, Zhang X, Su Y, Chan P, Xu E (2023) Effects of different Levodopa doses on blood pressure in older patients with early and middle stages of parkinson\u2019s disease. Heliyon 9:e17876. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17876","journal-title":"Heliyon"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08748-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08748-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:03:52Z","timestamp":1771347832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08748-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["8748"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08748-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"31 January 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that all procedures were in accordance with the ICH guidelines and Declaration of Helsinki. The study was reviewed and approved by the Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School (2024-596-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was provided by the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declared that there was no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}